Novo Nordisk signs $812m research deal with Deep Apple for non-GLP-1 drugs
Deep Apple is the latest biotech to be tapped by Novo Nordisk as the drugmaker aims to regain market share lost to Eli Lilly.
Deep Apple is the latest biotech to be tapped by Novo Nordisk as the drugmaker aims to regain market share lost to Eli Lilly.
What's Your Reaction?
